Pfizer has officially closed on its $10 billion purchase of obesity drug maker Metsera. So what does everyone think of the ...

Pfizer beats Q3 estimates, raises FY guidance, acquires Metsera for obesity drugs, and offers a 7% yield. Read here for an ...

Pfizer on Thursday closed its up to $10 billion acquisition of Metsera after winning shareholder approval, gaining a foothold ...

Shares of Metsera fell over 15% in premarket trading on Monday, after the weight-loss drug developer accepted a sweetened ...

Pfizer said on Thursday it completed an acquisition worth up to $10 billion of biotech firm Metsera after winning shareholder ...

(Reuters) -Metsera shareholders on Thursday approved Pfizer's takeover offer worth up to $10 billion, as per preliminary ...

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker ...

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...

Pfizer CEO Albert Bourla told Yahoo Finance that Pfizer has a "right to win" on the obesity drugs that have become a major ...

Speaking at a conference this morning, Pfizer CEO Albert Bourla suggested that Metsera’s therapies could begin hitting the ...